Straits Times Index
3,280.10 -7.65 (-0.23%) Nikkei
37,934.76 +306.28 (+0.81%) Hang Seng
17,651.15 +366.61 (+2.12%) FTSE 100
8,139.83 +60.97 (+0.75%) Bitcoin USD
63,945.93 -611.66 (-0.95%) CMC Crypto 200
1,329.74 -66.80 (-4.78%)
Pfizer Inc. (PFE)
After hours:
| Previous close | 25.26 |
| Open | 25.33 |
| Bid | 25.43 x 4000 |
| Ask | 25.46 x 2900 |
| Day's range | 25.20 - 25.54 |
| 52-week range | 25.20 - 40.37 |
| Volume | |
| Avg. volume | 42,220,991 |
| Market cap | 143.829B |
| Beta (5Y monthly) | 0.57 |
| PE ratio (TTM) | 68.65 |
| EPS (TTM) | 0.37 |
| Earnings date | 01 May 2024 |
| Forward dividend & yield | 1.68 (6.65%) |
| Ex-dividend date | 09 May 2024 |
| 1y target est | 31.10 |
Barrons.comPfizer Receives FDA Approval for Bleeding Disorder Treatment
Pfizer has received approval from the Food and Drug Administration for a rare genetic bleeding disorder treatment—the drug-maker’s first gene therapy to be approved in the U.S. The treatment, Beqvez, is for adults with moderate to severe hemophilia B—a disorder that prevents normal blood clotting—and will be available by prescription to eligible patients this quarter, according to the company. “Many people with hemophilia B struggle with the commitment and lifestyle disruption of regular FIX infusions, as well as spontaneous bleeding episodes, which can lead to painful joint damage and mobility issues,” said Adam Cuker, director of University of Pennsylvania’s Comprehensive Hemophilia and Thrombosis Program.
ZacksGear Up for Pfizer (PFE) Q1 Earnings: Wall Street Estimates for Key Metrics
Beyond analysts' top -and-bottom-line estimates for Pfizer (PFE), evaluate projections for some of its key metrics to gain a better insight into how the business might have performed for the quarter ended March 2024.
ZacksAbbVie (ABBV) Beats Q1 Earnings and Revenue Estimates
AbbVie (ABBV) delivered earnings and revenue surprises of 2.21% and 2.65%, respectively, for the quarter ended March 2024. Do the numbers hold clues to what lies ahead for the stock?
